Stay updated with breaking news from Director Michael Ackermann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) was the target of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 386,800 shares, a decrease of 32.2% from the April 30th total of 570,200 shares. Based on an average daily volume of 151,200 shares, the […]
Wall Street brokerages predict that Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) will report $16.67 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Tarsus Pharmaceuticals’ earnings, with estimates ranging from $15.00 million to $20.00 million. Tarsus Pharmaceuticals reported sales of $22.02 million during the same […]